NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

hyperopia,

Excellent summary. One additional and very important improvement that will be made in the next trial(s) is spacing of treatments which will be brought down to about 2 weeks at least initially. The reason for this is the effect of hypoxia (low oxygen) in the tumor microenvironment that drives out on site DCs in this time frame which is due to a gene switch being triggered that causes premature off site mobilization. This takes the necessary on site inflammatory DC signaling with them which allows macrophages and Tregs to take over before the next injection has a chance to continue the work already done by the on site DCs.
The many improvements that will be employed in the next trial(s) will create stunning results that won’t be limited to just the likely pancreatic trial that Direct and DCVax-DR are likely to be compared to each other in. I expect both to be very effective and that the activation methods will likely be selected based on how fast each one works and how well long term immune memory is activated by each which will likely be followed up on longer term after the initial success of both.
Again great job posting this summary. Best wishes.